Literature DB >> 33201054

Clinical and Histological Characterization of Toxic Keratopathy From Depatuxizumab Mafodotin (ABT-414), an Antibody-Drug Conjugate.

Brian A Lee1, Michael S Lee, Amanda C Maltry, Joshua H Hou.   

Abstract

PURPOSE: To report the histological findings and clinical course of 2 patients with microcyst-like epithelial keratopathy (MEK) associated with antibody-drug conjugate, depatuxizumab mafodotin.
METHODS: Case series.
RESULTS: Two patients with glioblastoma multiforme participating in a phase 3 clinical trial of the antibody-drug conjugate, depatuxizumab mafodotin, presented with bilateral MEK. Confocal imaging showed multiple large, round, hyperreflective lesions in the epithelium. Epithelial debridement was performed for symptomatic relief in both patients. Along with aggressive lubrication, bandage contact lenses, and reduction in the chemotherapeutic dose to maintenance levels, both patients experienced symptomatic improvement. However, MEK lesions recurred after re-epithelialization. Immunohistochemistry of the diseased epithelium showed immunoglobulin (Ig)G-positive granular cytoplasmic inclusions and increased cell apoptosis.
CONCLUSIONS: Depatuxizumab mafodotin accumulates in the basal corneal epithelium resulting in MEK because of increased apoptosis. Frequent lubrication and bandage contact lenses can provide symptom relief.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33201054     DOI: 10.1097/ICO.0000000000002595

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  2 in total

1.  Corneal Findings Associated to Belantamab-Mafodotin (Belamaf) Use in a Series of Patients Examined Longitudinally by Means of Advanced Corneal Imaging.

Authors:  Rita Mencucci; Michela Cennamo; Ludovica Alonzo; Carlotta Senni; Aldo Vagge; Lorenzo Ferro Desideri; Vincenzo Scorcia; Giuseppe Giannaccare
Journal:  J Clin Med       Date:  2022-05-19       Impact factor: 4.964

2.  Belantamab mafodotin associated corneal microcyst-like epithelial changes.

Authors:  Katherine Chuang; Roberto Pineda; Shaohui Liu
Journal:  Am J Ophthalmol Case Rep       Date:  2022-02-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.